Search
Brinzolamide
go.drugbank.com/drugs/DB01194Approved[A2051] Unlike [dorzolamide], brinzolamide has a higher lipophilicity to facilitate diffusion across the blood-retinal barrier. … Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma.
Mixtures: BRİTİL-T 10 MG/ML + 5 MG/ML GÖZ DAMLASI, SÜSPANSİYON, 1 ADETAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme.
Ticagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigational[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.
Products: NaRomosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalIn a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months … Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to
Human thrombin
go.drugbank.com/drugs/DB11571ApprovedInvestigationalFurthermore, human thrombin is manufactured by chromatographic purification of prothrombin from cryo-poor plasma followed by activation with calcium chloride [FDA Label]. … This transformation mimics the final coagulation cascade step which involves the clotting mass that adheres to the wound surface and achieves hemostasis and sealing of open tissues.
Ebola Zaire vaccine (live, attenuated)
go.drugbank.com/drugs/DB15595ApprovedInvestigationalIt is highly contagious: human to human transmission occurs from contact with body fluids from infected patients. … [A189018] This vaccine was later sold to NewLink Genetics, a biotech company that held the license to the vaccine from 2010 to 2014, although the vaccine was not marketed.
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigationala procedure by increasing platelet counts to the optimal level ≥50,000 per microliter. … This approval was supported by results from the AVA-PED-301 phase 3 study, which demonstrated durable platelet responses and favorable safety in children with persistent or chronic immune thrombocytopenia
Dalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalModifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]. … Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072